Ascletis Pharma, Inc. announced the Investigational New Drug (IND) application approval by US FDA and initiation of global development of ASC22, a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B.
[Ascletis Pharma, Inc.]
7992332
{7992332:EEEEEEEE}
apa
50
1
170939
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
